5 billion people have access to medicine
2 billion to go

The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Quick access

Our research programmes

Access to
Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Visit this programme

Antimicrobial
Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Visit this programme

Access to
Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.

Visit this programme

View all news

Event - 08 Nov 2021

FT Global Pharmaceutical and Biotechnology Conference

On Monday 8 November 2021, Margo Warren will join the Financial Times' virtual Global Pharmaceutical and Biotechnology Conference to discuss pharma pipelines.

View upcoming events

Publication - 22 Sep 2021

The Methodology for the 2022 Access to Medicine Index

Read the full Methodology Report, which sets out how the next Index will measure and assess pharmaceutical companies’ efforts to improve access to medicine.

View all publications

What leaders say

"The Access to Medicine Index is a very important project. What gets measured, gets done."

Dr. Margaret Chan

Former Director General, World Health Organisation

"I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged."

Mary Robinson

President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)

"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."